Shockwave, which now operates under J&J’s MedTech division, offers the market’s only intravascular lithotripsy platform for coronary artery disease and peripheral disease, according to a J&J news release.
The company has been steadily growing its cardiovascular line after buying Abiomed in 2022 for $16.6 billion and Laminar in late 2023 for $400 million. The latest acquisition has propelled J&J to be a “leader in four of the largest and highest-growth medtech markets within cardiovascular intervention,” the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
